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Objective: The purpose of this study was to assess the association between the rs17173608 chemerin
polymorphism and polycystic ovary syndrome risk (PCOS).
Materials and methods: This caseecontrol study was performed on 150 patients with PCOS and 150
normal women as the control group. Tetra-ampliﬁcation refractory mutation systemepolymerase chain
reaction was used to detect the polymorphism.
Results: Our ﬁnding showed a positive association between the chemerin gene rs17173608 poly-
morphism and risk of PCOS. In the dominant effect of the G allele (comparison between TGþGG and TT),
TGþGG genotypes were associated with the risk of PCOS (odds ratio ¼ 2; 95% conﬁdence interval ¼ 1.3
e3.2, p ¼ 0.003). The G allele is thus dominant and increases the risk of PCOS as compared to the T allele
(odds ratio ¼ 1.7, 95% conﬁdence interval ¼ 1.1e2.5, p ¼ 0.009). Nonetheless, there was no signiﬁcant
association between chemerin rs17173608 gene polymorphism and PCOS after adjusting genotypes for
body mass index and age.
Conclusion: These results suggested that there was a signiﬁcant association between chemerin
rs17173608 polymorphism and the PCOS; but this relationship was affected by obesity status.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Polycystic ovary syndrome (PCOS), one of the most common
endocrinopathy, affects 5e10% of women in the reproductive age
and is characterized by menstrual dysfunction and hyper-
androgenism and polycystic ovaries (PCO) [1,2]. It is linked to
metabolic alterations such as hyperinsulinemia, insulin resistance,
impaired glucose tolerance, type 2 diabetes, dyslipidemia, and
visceral obesity [3]. Approximately 50% of PCOS patients are obese
and have a great risk for overweight and central obesity [4].
Adipose tissue secretes a variety of hormones and cytokines
named adipokines having widespread effects on reproduction,
immune response, and carbohydrate and lipid metabolism [5].
They appear to play a crucial role in the pathogenesis of obesity,
insulin resistance, metabolic syndrome, and diabetes [6]. The
consequent hyperinsulinemia is more prevalent in lean and obesemic Azad University, Arsanjan
l./fax: þ98 7143522483.
ahoo.com (L. Kohan).
bstetrics & Gynecology. Publishedwomenwith PCOS when compared with age- and weight-matched
normal women [7].
Chemerin, also known as tazarotene-induced gene 2 (TIG2) or
retinoic acid receptor responder 2 (RARRES2), is a novel adipokine
identiﬁed as a chemoattractant protein by Wittamer et al [8].
Chemerin was recently described to be associated with obesity
and metabolic syndrome [9,10]. PCOS has also been recognized as a
metabolic disorder, manifested by abdominal obesity, insulin resis-
tance, dyslipidemia and hypertension. Serum chemerin levels are
higher in obese women and PCOS patients [2,11,12]. Genetic poly-
morphism can effect gene expression and plays a signiﬁcant role in
phenotypic variation disease susceptibility [13]. In this study, we
evaluated for the ﬁrst time, association between rs17173608 poly-
morphism in the chemerin gene and susceptibility of PCOS.
Materials and methods
Patients
This study included 150 women with PCOS (mean ± standard
deviation age, 28.06 ± 5 years) recruited from an infertility andby Elsevier Taiwan LLC. All rights reserved.
Table 1
The anthropometric characteristics of the study population.
PCOS Controls p
Age (y) 28 ± 5 30.72 ± 5.5 < 0.01
Height (cm) 1.61 ± 7.14 1.61 ± 7.18 0.9
Weight (kg) 69.3 ± 13.8 64.9 ± 11.6 0.004
BMI (kg/m2) 26.7 ± 5.2 24.87 ± 4.9 0.003
BMI ¼ body mass index; PCOS ¼ polycystic ovary syndrome.
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of PCOS was based on the criteria proposed by the Rotterdam
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group [14].
Age frequency-matched controls were randomly selected from the
healthy female blood donors, according to the age distribution of
the cases. A total of 150 healthy females (mean ± standard devia-
tion age, 30.72 ± 5.5 years) participated in the study. Control in-
dividuals were healthy volunteers or endocrinology outpatients
without any endocrine related diseases except for simple over-
weight/obesity. Body mass index (BMI) was calculated as weight in
kg divided by (height)2 in m2. Both case and control groups
belonged to the same ethnic/religious (Caucasian/Muslim) group.
Informed consent was obtained from each participant before the
study. Blood samples were collected in EDTA-containing tubes. The
study was approved by the Ethics Committee of Shiraz University of
Medical Sciences, Shiraz, Iran.Genotyping
Genomic DNA was isolated from whole blood [15]. The geno-
types were examined using tetra-ampliﬁcation refractory mutation
systemepolymerase chain reaction (T-ARMS-PCR) assay as
described previously [16]. To certify genotyping quality, the poly-
morphism in random samples was regenotyped. No discrepancies
were discovered upon replicating testing. To test for contamination,
tubes containing the PCR mixture without the DNA template were
included in every run as negative controls.Statistical analysis
A Chi-square test was performed for the polymorphism to
determine if the control and patient samples demonstrated Har-
dyeWeinberg equilibrium.
Genotype and allelic frequencies were compared between the
case and control groups by Chi-square test. Logistic regression
analysis was also applied to estimate odds ratio (OR) and 95%
conﬁdence interval (CI) of genetic risk in PCOS. A p value < 0.05
was considered statistically signiﬁcant. Data analyses were per-
formed using SPSS software version 18.0 (SPSS Inc., Chicago, IL,
USA).Fig. 1. Electrophoresis pattern of tetra-ampliﬁcation refractory mutation
systemepolymerase chain reaction for detection of chemerin rs17173608. M ¼ 100 bp
DNA marker.Results
The electrophoresis pattern of T-ARMS-PCR for detection of
chemerin rs17173608 polymorphism is shown in Fig. 1. PCR product
sizes were 262 bp for G allele, 332 bp for T allele, and 549 bp for
control band.
Anthropometric characteristics of the study population are
shown in Table 1. There was a signiﬁcant difference in BMI between
the PCOS patients and control group (p ¼ 0.003). Classiﬁcation of
BMI was: normal (18.5e24.9 kg/m2); overweight (25e29.9 kg/m2);
and obese ( 30 kg/m2). Logistic regression analysis showed that a
signiﬁcant association between PCOS risk and obese status
(OR ¼ 1.96, 95%CI ¼ 0.99e3.9, p ¼ 0.03; Table 2).
The genotype and allele frequencies of the chemerin T/G single
nucleotide polymorphism (rs17173608) in PCOS patients and con-
trol were shown in Table 3. The genotype distributions of the single
nucleotide polymorphism were in the HardyeWeinberg equilib-
rium in both patients and controls (p > 0.05). As shown in Table 3,
there was a signiﬁcant difference in the distribution of TG genotype
between PCOS patients and controls. In the dominant effect of the G
allele (comparison between GGþTG vs. TT), GGþTG genotypes
signiﬁcantly increased the risk of PCOS (OR ¼ 2, 95% CI ¼ 1.3e3.2,
p ¼ 0.003). By contrast, in the recessive effect of the G allele
(comparison between GG vs. TTþTG), GG genotype was not asso-
ciated with the risk of PCOS (OR ¼ 1.6, 95% CI ¼ 0.52e5.1, p ¼ 0.4).
The minor allele frequency (G allele) of rs17173608 polymorphism
in patients with and without PCOS was 0.27 and 0.18, respectively.
There was a signiﬁcant association between G allele and PCOS risk
(OR: 1.7, 95% CI ¼ 1.1e2.5, p ¼ 0.009).
To assess the association of the chemerin rs17173608 poly-
morphism with the risk of PCOS, crude OR and adjusted OR were
calculated with and without adjusting for BMI (Table 3). After
adjusting for BMI and age by logistic regression analysis, no sig-
niﬁcant association was observed between chemerin rs17173608
and PCOS risk.Discussion
Our study is the ﬁrst investigation to examine whether
rs17173608 polymorphism in the chemerin gene contributed to
susceptibility to PCOS in Shiraz, southeast Iran. In this study, we
present novel ﬁndings of an association between genetic variants
chemerin rs17173608 gene polymorphism and risk of PCOS. The
chemerin rs17173608 polymorphism increased the risk of PCOS in
our population, but there was no association between chemerinTable 2
Association of body mass index (BMI) status with polycystic ovary syndrome (PCOS)
risk.
Variable Classiﬁcation Controls (%) PCOS (%) OR (95%CI) p
BMI Normal 76 (55.9) 57 (42.2) 1 d
Overweight 41 (30.1) 50 (37) 1.6 (0.95e2.8) 0.07
Obesity 19 (14) 28 (20.7) 1.96 (0.99e3.9) 0.03
CI ¼ conﬁdence interval; OR ¼ odds ratio.
Table 3
Association of the chemerin rs17173608 gene polymorphism with the risk of polycystic ovary syndrome (PCOS).
Chemerin rs17173608 polymorphism PCOS (%) Control (%) OR (95% CI) p OR (95% CI)a p*
Codominant
TT 102 (57) 77 (43) 1 d 1 d
TG 43 (39.8) 65 (60.2) 2 (1.2e3.2) 0.005 1.8 (0.77e4.1) 0.17
GG 5 (38.5) 8 (61.5) 2/1 (0.66e6.7) 0.2 3.1 (0.48e19) 0.23
Dominant
TT 1.2 (57) 77 (43) 1 d 1 d
TGþGG 48 (39.7) 73 (60.3) 2 (1.3e3.2) 0.003 1.78 (0.77e4.1) 0.17
Recessive
TTþGT 145 (50.5) 142 (49.5) 1 d 1 d
GG 5 (38.5) 8 (61.5) 1.6 (0.52e5.1) 0.4 1.7 (0.33e8.9) 0.5
Alleles
T 246 (82) 219 (0.73) 1
G 54 (18) 81 (27) 1.7 (1.1e2.5) 0.009
CI ¼ conﬁdence interval; OR ¼ odds ratio.
a Adjusted for body mass index and age.
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Chemerin is an adipokine that plays a role in adipogenesis,
adipocyte metabolism, glucose metabolism and regulation of im-
munity [17,18]. Bozaoglu et al [9] reported that plasma chemerin
levels are strongly associated with BMI, plasma TG, and blood
pressure, features of the metabolic syndrome. Chemerin can
regulate insulin sensitivity and insulin secretion. Conversely, in-
sulin induces chemerin release from adipocytes [19]. It is known
that serum chemerin level is elevated in PCOS patients compared
with controls. Tan et al [11] detected signiﬁcant increase in serum
chemerin, and subcutaneous and omental adipose tissue chemerin
mRNA level and protein expression in PCOS patients. Additionally,
metformin, a drug for treatment of PCOS patients with insulin
resistance, decrease serum chemerin level [11]. Several studies
reported that chemerin mRNA was expressed in the ovaries of
human, rat, and mouse [2,8,9,18]. Wang et al [2] found that
expression of chemerin and its chemR23 receptor were increased in
the ovaries of 5a-dihydrotestestrone-induced rat model at both
mRNA and protein levels. Chemerin can negatively regulate FSH-
induced follicular steroidogenesis and thus contribute to the
pathogenesis of PCOS [17].
To date, there is no study regarding the impact of chemerin
polymorphism on PCOS risk. Müssing et al [20] have found an as-
sociation between chemerin rs17173608 and rs10278590 poly-
morphisms and visceral adipose tissue. Hashemi et al [16] have also
reported chemerin rs17173608 polymorphism increased the risk of
methabolic syndrome. They found a signiﬁcant association be-
tween G allele and risk of methabolic syndrome. This poly-
morphism is located in intron 2 of the chemerin gene. The introns
are major targets for mutations because of long sequences
harboring functional elements, including intron splice enhancers,
silencers, and cis-acting RNA elements that regulate alternative
splicing [21]. Although the precise mechanisms through which it
exerts its effect on chemerin gene expression remain unclear, the
rs17173608 polymorphism in the intronic region of chemerin ap-
pears to show potential clinical signiﬁcance. In the present study,
we found that the G allele increased risk of PCOS; nevertheless,
after adjusting for BMI and age, there was no association between
chemerin rs17173608 polymorphism and PCOS susceptibility.
Obesity is a very common clinical feature in women affected by
PCOS. In fact, approximately 50% of PCOS women are overweight or
obese and the history of the weight gain frequently precedes the
onset of oligomenorrhea and hyperandrogenism, suggesting a
pathogenic role of obesity in the subsequent development of the
syndrome [22]. Chemerin map on 7q36.1 encodes an inactive form
as prochemerin and is activated through the cleavage of the C-terminus by inﬂammatory and coagulation serine protease [8].
Thus, chemerin may provide an exciting connection between
obesity, inﬂammation, and obesity-related pathophysiological
change in humans.
In conclusion, our ﬁndings showed that rs17173608 poly-
morphism in the chemerin gene is associated with PCOS suscepti-
bility but this association is affected by BMI and age, because after
eliminating the effect of these factors, there was no association
between this polymorphism and PCOS risk. Larger studies with
different ethnicities are required to validate our ﬁndings.
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